Dubois Severine G, Heilbronn Leonie K, Smith Steven R, Albu Jeanine B, Kelley David E, Ravussin Eric
Health and Performance Enhancement Division, Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA.
Obesity (Silver Spring). 2006 Sep;14(9):1543-52. doi: 10.1038/oby.2006.178.
Our objective was to delineate the potential role of adipogenesis in insulin resistance and type 2 diabetes. Obesity is characterized by an increase in adipose tissue mass resulting from enlargement of existing fat cells (hypertrophy) and/or from increased number of adipocytes (hyperplasia). The inability of the adipose tissue to recruit new fat cells may cause ectopic fat deposition and insulin resistance.
We examined the expression of candidate genes involved in adipocyte proliferation and/or differentiation [CCAAT/enhancer-binding protein (C/EBP) alpha, C/EBPdelta, GATA domain-binding protein 3 (GATA3), C/EBPbeta, peroxisome proliferator-activated receptor (PPAR) gamma2, signal transducer and activator of transcription 5A (STAT5A), Wnt-10b, tumor necrosis factor alpha, sterol regulatory element-binding protein 1c (SREBP1c), 11 beta-hydroxysteroid dehydrogenase, PPARG angiopoietin-related protein (PGAR), insulin-like growth factor 1, PPARgamma coactivator 1alpha, PPARgamma coactivator 1beta, and PPARdelta] in subcutaneous adipose tissue from 42 obese individuals with type 2 diabetes and 25 non-diabetic subjects matched for age and obesity.
Insulin sensitivity was measured by a 3-hour 80 mU/m2 per minute hyperinsulinemic glucose clamp (100 mg/dL). As expected, subjects with type 2 diabetes had lower glucose disposal (4.9 +/- 1.9 vs. 7.5 +/- 2.8 mg/min per kilogram fat-free mass; p < 0.001) and larger fat cells (0.90 +/- 0.26 vs. 0.78 +/- 0.17 microm; p = 0.04) as compared with obese control subjects. Three genes (SREBP1c, p < 0.01; STAT5A, p = 0.02; and PPARgamma2, p = 0.02) had significantly lower expression in obese type 2 diabetics, whereas C/EBPbeta only tended to be lower (p = 0.07).
This cross-sectional study supports the hypothesis that impaired expression of adipogenic genes may result in impaired adipogenesis, potentially leading to larger fat cells in subcutaneous adipose tissue and insulin resistance.
我们的目的是阐明脂肪生成在胰岛素抵抗和2型糖尿病中的潜在作用。肥胖的特征是现有脂肪细胞增大(肥大)和/或脂肪细胞数量增加(增生)导致脂肪组织量增加。脂肪组织无法募集新的脂肪细胞可能会导致异位脂肪沉积和胰岛素抵抗。
我们检测了42名2型糖尿病肥胖个体和25名年龄及肥胖程度匹配的非糖尿病受试者皮下脂肪组织中参与脂肪细胞增殖和/或分化的候选基因[CCAAT/增强子结合蛋白(C/EBP)α、C/EBPδ、GATA结构域结合蛋白3(GATA3)、C/EBPβ、过氧化物酶体增殖物激活受体(PPAR)γ2、信号转导和转录激活因子5A(STAT5A)、Wnt-10b、肿瘤坏死因子α、固醇调节元件结合蛋白1c(SREBP1c)、11β-羟基类固醇脱氢酶、PPARG血管生成素相关蛋白(PGAR)、胰岛素样生长因子1、PPARγ辅激活因子1α、PPARγ辅激活因子1β和PPARδ]的表达。
通过3小时每分钟80 mU/m²的高胰岛素血糖钳夹(100 mg/dL)测量胰岛素敏感性。正如预期的那样,与肥胖对照受试者相比,2型糖尿病受试者的葡萄糖处置能力较低(4.9±1.9对7.5±2.8 mg/min每千克去脂体重;p<0.001),脂肪细胞较大(0.90±0.26对0.78±0.17微米;p = 0.04)。三个基因(SREBP1c,p<0.01;STAT5A,p = 0.02;和PPARγ2,p = 0.02)在肥胖2型糖尿病患者中的表达显著降低,而C/EBPβ仅呈降低趋势(p = 0.07)。
这项横断面研究支持以下假设,即脂肪生成基因表达受损可能导致脂肪生成受损,潜在地导致皮下脂肪组织中脂肪细胞增大和胰岛素抵抗。